Lapatinib (GW572016) a Dual Inhibitor of EGFR and ErbB2, for Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus.
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Lapatinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 14 Feb 2008 The expected completion date for this trial is now 1 Sep 2007.
- 16 Jan 2008 Status changed from recruiting to discontinued.
- 28 Jul 2006 New trial record.